Clinical Scorecard: Advances in Cholangiocarcinoma Treatment

At a Glance

Key Highlights

• The article reports that screening is not currently available because known biomarkers are lacking.
• The article says surgical resection followed by chemotherapy historically offered the best chance for longer-term survival; about 20%–30% of patients are eligible, and recurrence remains high.
• The article describes liver transplantation for selected patients with small, unresectable tumors localized to the liver and no metastases; fewer than 5% of patients qualify.
• The article identifies chemotherapy combined with immunotherapy as the standard first-line treatment for advanced or metastatic bile duct cancer.
• Molecular profiling can identify tumor mutations that may help guide targeted treatment.

Guideline-Based Recommendations

Diagnosis

• The article reports that cholangiocarcinoma is often detected when locally advanced or metastatic because symptoms may not appear until later stages and screening options are lacking.
• The article says molecular profiling can identify tumor mutations that may inform treatment selection.

Management

• The article says surgical resection followed by chemotherapy historically offered the best chance for longer-term survival in eligible patients.
• The article describes chemotherapy plus immunotherapy as the standard first-line treatment for advanced or metastatic bile duct cancer.
• The article describes liver transplantation for selected patients with small, unresectable tumors localized to the liver and no metastases.

Monitoring & Follow-up

• The article notes that recurrence after surgical resection remains high but does not specify a monitoring schedule.

Risks

• The article says tumor location, poor liver function, or metastatic disease can make resection impossible or too dangerous.
• The article quotes a specialist describing the bile duct as difficult to image or operate on and noting that tumors can affect nearby vessels even when small.

Patient & Prescribing Data

Patients with cholangiocarcinoma; the article describes treatment eligibility in relation to disease extent, tumor location, liver function, and metastasis.

The article reports that gemcitabine plus cisplatin became a standard chemotherapy combination in the 2010s and describes chemotherapy plus immunotherapy as the current first-line treatment for advanced or metastatic disease. It also says molecular profiling may help guide targeted therapies.

Clinical Best Practices

• The article describes resection eligibility as affected by tumor location, liver function, and metastatic status.
• The article describes transplant eligibility as limited to selected patients with small, unresectable, non-metastatic tumors localized to the liver.
• The article says molecular profiling can identify mutations that may inform targeted treatment.

Related Resources & Content